...
首页> 外文期刊>Journal of Structural Biology >One of the possible mechanisms of amyloid fibrils formation based on the sizes of primary and secondary folding nuclei of A beta 40 and A beta 42
【24h】

One of the possible mechanisms of amyloid fibrils formation based on the sizes of primary and secondary folding nuclei of A beta 40 and A beta 42

机译:基于A beta 40和A beta 42的一级和二级折叠核大小的淀粉样蛋白原纤维形成的可能机制之一

获取原文
获取原文并翻译 | 示例

摘要

In the presented paper, theoretical as well as electron microscopy and X-ray diffraction experimental approaches were employed for studding the process of A beta amyloid formation. Using quantitative estimates of a number of monomers which form the nuclei of amyloid fibrils the sizes of folding nuclei of amyloid fibrils for A beta 40 and 42 have been determined for the first time. We have shown that the size of the primary nucleus of A beta 42 peptide fibrils corresponds to 3 monomers, the size of the secondary nucleus for this peptide is 2 monomers. Applying the same analysis to A beta 40 we conclude that the size of the primary nucleus is 2 monomers, and the size of the secondary nucleus is one monomer. Summation of our theoretical and experimental results has allowed us to propose a new model of the structural organization of amyloid fibrils. Our model suggests that the generation of fibrils takes place along the following simplified pathway: a monomer -> a ring oligomer -> a mature fibril consisting of ring oligomers. These data shed more light upon our understanding of what sizes of the oligomers could represent main targets for future therapies (tetramers for A beta 42 and trimers for A beta 40), and aid in the development of inhibitors of A beta 40 and 42 oligomer formation. (C) 2016 Published by Elsevier Inc.
机译:在本文中,采用理论以及电子显微镜和X射线衍射实验方法来研究Aβ淀粉样蛋白的形成过程。使用对形成淀粉样蛋白原核的许多单体的定量估计,首次确定了Aβ40和42的淀粉样原蛋白折叠核的大小。我们已经显示,A beta 42肽原纤维的初级核的大小对应于3个单体,该肽的次级核的大小是2个单体。将相同的分析应用于A beta 40,我们得出的结论是,一次核的大小为2个单体,而二次核的大小为一个单体。我们的理论和实验结果的总结使我们能够提出淀粉样蛋白原纤维结构组织的新模型。我们的模型表明,原纤维的生成是通过以下简化途径进行的:单体->环状低聚物->由环状低聚物组成的成熟原纤维。这些数据使我们更加了解低聚物的大小可以代表未来治疗的主要目标(A beta 42的四聚物和A beta 40的三聚体),并有助于开发A beta 40和42的低聚物抑制剂。 。 (C)2016由Elsevier Inc.发布

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号